Data on investigational drug TMC207 for MDR-TB published in New England Journal of Medicine

[Mechelen Belgium, June 3, 2009] ?Interim results from an ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207 for the treatment of multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine today. TMC207 is being developed by Tibotec BVBA.

Read the whole article on Science Blog

More from Science Blog